This historic move gives hope to women.
The US Food and Drug Administration has approved a drug that can treat postpartum depression, a mental illness affecting new mothers.
The drug will be sold as Zulresso and its clinical trials have been shown to work within hours of postpartum depression symptoms. The mental illness is known to impact one in nine new mothers immediately after giving birth.
Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products in the FDA’sCenter for Drug Evaluation and Research, said in a press announcement:
“Postpartum depression is a serious condition that, when severe, can be life-threatening. Women may experience thoughts about harming themselves or harming their child. Postpartum depression can also interfere with the maternal-infant bond. This approval marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option.”
To read the original story, click here.
